Premium
Current status of tamoxifen use: An update for the surgical oncologist
Author(s) -
Heerdt Alexandra S.,
Borgen Patrick I.
Publication year - 1999
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/(sici)1096-9098(199909)72:1<42::aid-jso13>3.0.co;2-e
Subject(s) - medicine , tamoxifen , breast cancer , disease , oncology , radiation oncologist , psychological intervention , cancer , gynecology , intensive care medicine , radiation therapy , psychiatry
The surgical oncologist is frequently responsible for the screening and diagnosis of women with breast cancer. In this pivotal role, they are often the first to discuss treatment options, including nonsurgical interventions, with breast cancer patients. Recent long‐term clinical trial data provide support for the use of tamoxifen to prevent breast cancer in women at high risk of the disease. A breast cancer risk assessment can help identify women at higher than average risk for the disease, who may be appropriate candidates for chemoprevention. It is important for the surgical oncologist to understand the current indications and evidence regarding the use of tamoxifen for breast cancer prevention and treatment as they counsel their patients on available options. J. Surg. Oncol. 1999;72:42–49. © 1999 Wiley‐Liss, Inc.